SynthesisFrontiers in oncology2025
Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Umbralisib, a dual PI3Kδ/CK-1ϵ inhibitor, has shown clinical activity in various hematologic malignancies. However, a systematic assessment of its efficacy and safety is still lacking. This study provides a comprehensive evaluation based on current clinical evidence. Methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, CNKI, and ClinicalTrials.gov for studies involving umbralisib in hematologic malignancies (up to March 14, 2025). Two investigators independently screened eligible studies and extracted data. Efficacy outcomes and adverse events (AEs) were analyzed using meta-analytic methods. The review protocol was registered in PROSPERO (registration number: CRD420251018098). Results: Umbralisib monotherapy was associated with frequent hematologic AEs such as thrombocytopenia, neutropenia, and anemia, along with common non-hematologic toxicities including diarrhea, nausea, and fatigue. Liver enzyme elevation and diarrhea represented the more severe AEs. Combination therapy showed a distinct AE profile, with infusion reactions and infections being more prominent, but generally demonstrated fewer severe toxicities. In terms of efficacy, monotherapy yielded a modest objective response rate, while combination regimens achieved substantially higher response rates, including improved complete and partial response outcomes. Conclusion: Umbralisib shows promising efficacy in hematologic malignancies such as MZL, FL, and DLBCL, though its clinical use is limited by frequent AEs. Combination therapy offers better response rates and appears to alleviate some of the severe toxicities seen with monotherapy. Further studies are needed to optimize combination strategies, explore alternative administration routes, and refine dosing approaches. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251018098.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.